Israeli stem cell therapeutics company BrainStorm Cell Therapeutics Ltd. (Bulletin Board:BCLI), which develops adult stem cell therapeutics for neurodegenerative diseases, has announced success in a clinical trial on ALS patients.

36 patients treated with the company’s stem cell treatment NurOwn exhibited slower degeneration than the twelve patients in the control group. “The study achieved its primary objective, demonstrating that NurOwn was safe and well tolerated. NurOwn also achieved multiple secondary efficacy endpoints, showing clear evidence of a clinically meaningful benefit. Notably, response rates were higher for NurOwn-treated subjects compared to placebo at all time points in the study out to 24 weeks,” the company said.

The results enable the company to continue its clinical trials. In the next trial patients will be treated several times and not only once. It is still not known whether the next trial will be larger than the current one, and whether it will be defined as a Phase 3 trial or an additional Phase 2 trial.

Read the entire article on Globes.

(YWN – Israel Desk, Jerusalem)